Cargando…

Incidence and Clinical Features of Drug-induced Lung Injury in Patients with Advanced Colorectal Cancer Receiving Cetuximab: Results of a Prospective Multicenter Registry

OBJECTIVE: We investigated the incidence and clinical features of drug-induced lung injury during cetuximab therapy in Japanese patients with colorectal cancer in a prospective multicenter registry based on a central registration system. METHODS: We investigated and followed up patients with or susp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Satoh, Taroh, Gemma, Akihiko, Kudoh, Shoji, Sakai, Fumikazu, Yamaguchi, Kensei, Watanabe, Toshiaki, Ishiguro, Megumi, Inoshiri, Shogo, Izawa, Makiko, Sugihara, Kenichi, Sakata, Yuh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214246/ https://www.ncbi.nlm.nih.gov/pubmed/25210144 http://dx.doi.org/10.1093/jjco/hyu128

Ejemplares similares

Severe Infusion Reactions to Cetuximab Occur within 1 h in Patients with Metastatic Colorectal Cancer: Results of a Nationwide, Multicenter, Prospective Registry Study of 2126 Patients in Japan
por: Yamaguchi, Kensei, et al.
Publicado: (2014)

A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(®)) in Patients with Metastatic Colorectal Cancer
por: Ishiguro, Megumi, et al.
Publicado: (2012)

Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
por: Sakata, Hidenori, et al.
Publicado: (2022)

Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: Incidence, mortality and clinical characterization
por: Yoshizawa, Kazutake, et al.
Publicado: (2014)

Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study
por: Osawa, Masahiro, et al.
Publicado: (2015)

BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2020)

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
por: Takegawa, Naoki, et al.
Publicado: (2015)

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer
por: Gemma, Akihiko, et al.
Publicado: (2014)

Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer
por: MASUDA, TAIKI, et al.
Publicado: (2016)

Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial
por: Muro, Kei, et al.
Publicado: (2019)

Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy
por: Yamaguchi, Toshifumi, et al.
Publicado: (2022)

Prognostic significance of Traf2- and Nck- interacting kinase (TNIK) in colorectal cancer
por: Takahashi, Hidenori, et al.
Publicado: (2015)

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
por: Baba, Hideo, et al.
Publicado: (2017)

Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study
por: Yoshino, Takayuki, et al.
Publicado: (2015)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
por: Ooki, Akira, et al.
Publicado: (2022)

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
por: Yoshikawa, Akie Kimura, et al.
Publicado: (2022)

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
por: Watanabe, Toshiaki, et al.
Publicado: (2015)

mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival
por: Yasuno, Masamichi, et al.
Publicado: (2019)

Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer
por: Ishiguro, Megumi, et al.
Publicado: (2012)

Investigation of Obstructive Sleep Apnea Using Portable Monitors and Health Check Data in Japanese Drivers
por: Ueyama, Masako, et al.
Publicado: (2018)

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
por: Satoh, Taroh, et al.
Publicado: (2014)

Reproduction of the Antitumor Effect of Cisplatin and Cetuximab Using a Three-dimensional Spheroid Model in Oral Cancer
por: Ono, Kisho, et al.
Publicado: (2022)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Successful Endoscopic Resection of an Early Carcinoma of the Duodenum
por: Tada, Tomoko, et al.
Publicado: (1999)

Impact of Trigger on Outcome of Takotsubo Syndrome　― Multi-Center Registry From Tokyo Cardiovascular Care Unit Network ―
por: Imori, Yoichi, et al.
Publicado: (2019)

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
por: Sawaki, Akira, et al.
Publicado: (2011)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
por: Watanabe, Toshiaki, et al.
Publicado: (2017)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Emphysema and Interstitial Pneumonia in Rheumatoid Arthritis
por: Sakai, Fumikazu
Publicado: (2018)

Clinical and MRI Characteristics of Uterine Cervical Adenocarcinoma: Its Variants and Mimics
por: Saida, Tsukasa, et al.
Publicado: (2019)

Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)
por: Ueno, Hideki, et al.
Publicado: (2021)

Association between chronic bacterial airway infection and prognosis of bronchiolitis obliterans syndrome after hematopoietic cell transplantation
por: Yomota, Makiko, et al.
Publicado: (2019)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors
por: Shitara, Kohei, et al.
Publicado: (2019)

The Effects of Oral L-Carnitine Supplementation on Physical Capacity and Lipid Metabolism in Chronic Hemodialysis Patients
por: Kudoh, Yasuo, et al.
Publicado: (2014)

Targeting the regulation of aberrant protein production pathway in gastrointestinal cancer treatment
por: Sato, Hiromichi, et al.
Publicado: (2022)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

Cetuximab in Refractory Skin Cancer Treatment
por: Kalapurakal, Sini J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_u5vb8gmmo4569t7dspaq70100p